Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more
Anebulo Pharmaceuticals Inc (ANEB) - Total Assets
Latest total assets as of December 2025: $9.42 Million USD
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) holds total assets worth $9.42 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anebulo Pharmaceuticals Inc - Total Assets Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Anebulo Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Anebulo Pharmaceuticals Inc's total assets of $9.42 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.7% |
| Accounts Receivable | $73.22K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anebulo Pharmaceuticals Inc's current assets represent 98.5% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 95.7% of total assets in 2025, down from 99.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Anebulo Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Anebulo Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Anebulo Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Anebulo Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Anebulo Pharmaceuticals Inc is currently not profitable relative to its asset base.
Anebulo Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.71 | 17.52 | 13.30 |
| Quick Ratio | 16.71 | 17.52 | 13.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.72 Million | $ 14.52 Million | $ 3.61 Million |
Anebulo Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Anebulo Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 198.2% |
| Total Assets | $12.15 Million |
| Market Capitalization | $3.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anebulo Pharmaceuticals Inc's assets below their book value (0.30 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Anebulo Pharmaceuticals Inc's assets grew by 198.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual total assets of Anebulo Pharmaceuticals Inc from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $12.15 Million | +198.19% |
| 2024-06-30 | $4.07 Million | -65.10% |
| 2023-06-30 | $11.67 Million | -25.09% |
| 2022-06-30 | $15.58 Million | -28.05% |
| 2021-06-30 | $21.65 Million | +615.00% |
| 2020-06-30 | $3.03 Million | -- |